Peptide Quality, Purity, COAs & Analytical Testing

Peptide quality is not one number. It is a set of related but distinct questions, each answered by a different kind of analytical evidence. No card below ranks or scores a sample -- each simply names the question its evidence category answers, and the question it does not.

HPLC purity is a relative separation/impurity profile under a defined method. Assay, content, or strength is the quantity of target peptide actually present. ICH Q6A treats identification, assay/content, and impurity testing as distinct specification categories, and states that a specific, stability-indicating procedure should be used to determine content/strength.

Possible content approaches include a calibrated HPLC assay against a characterized reference standard, amino-acid analysis, mass-balance value assignment, quantitative NMR in appropriate applications, and validated quantitative LC-MS approaches. These can be related to a purity number but are not interchangeable with it.

A 2023 USP-authored peer-reviewed paper on synthetic peptide reference standards gives a theoretical mass-balance example: material with 0.92% total HPLC-detected impurity area (99.08% main chromatographic basis) also carried 5.58% w/w acetic acid, 0.003% w/w TFA, 0.003% w/w residual solvents, and 0% residue on ignition -- and once those measured mass components are included, the mass-balance result corresponds to approximately 0.93 mg of peptide free base per mg of material. This is a teaching example from that specific reference-standard paper, not a universal peptide correction factor.

Retention time depends on the chromatographic system and conditions. It becomes more useful when compared to a qualified reference standard under the same method, combined with spectral or mass information, or used as one component of a validated identity procedure -- but it should not be presented as a universal molecular fingerprint across laboratories or methods.

ICH Q6A states that identification solely by a single chromatographic retention time is not regarded as a specific identity test; combinations such as HPLC/MS can provide stronger specificity.

Synthetic peptides are frequently isolated as salts. Counterions can include trifluoroacetate (TFA), acetate, chloride, or others depending on synthesis, purification, and formulation, and peer-reviewed methods demonstrate that counterions can be quantitatively measured by ion chromatography, capillary electrophoresis, mixed-mode chromatography, and related methods.

Counterion mass matters when interpreting peptide content: a vial can show high chromatographic peptide purity while a nontrivial portion of its dry mass consists of counterion. Counterion form can also affect physicochemical behavior in some systems, so salt identity should be reported when scientifically relevant.

ICH Q3C defines residual solvents as organic volatile chemicals used or produced during the manufacture of drug substances, excipients, or products. Gas chromatography is commonly used for residual-solvent testing, and this analytical question is distinct from peptide-related HPLC purity.

Potential peptide-related impurity classes can include deletion sequences, insertion sequences, truncated sequences, incompletely deprotected products, epimers or other stereochemical impurities, oxidation products, deamidation products, hydrolysis or clipping products, aggregates or oligomeric species where relevant, and process-related impurities. Not every peptide sample carries every impurity class -- these are categories a sensitive, orthogonal analytical program may need to distinguish, not a checklist every material is expected to show.

Current 2026 FDA activity for revised product-specific guidances for certain generic peptide products emphasizes impurity thresholds and profiles, higher-order structure, biological activity, and innate immune-response testing. FDA withdrew its May 2021 general synthetic-peptide guidance in July 2026 because it no longer reflected current scientific thinking, and this page does not use that withdrawn guidance as current regulatory authority.

Sterility, bacterial endotoxin, and bioburden are separate microbiological quality questions, each with its own recognized test chapter. A sample can pass one of these dimensions without proving another, and a complete injectable-product quality program can require multiple distinct microbiological attributes.

A test result is only as useful as the method that produced it. ICH Q2(R2), finalized by FDA in March 2024, provides the current general framework for validating analytical procedures, covering specificity/selectivity, accuracy, precision, analytical range/response, detection/quantitation capability where relevant, robustness, and system suitability where appropriate.

A report meaningfully characterizes only the sample/lot actually tested. 21 CFR 211.194 requires GMP laboratory records to identify the sample source, lot number or distinctive code, dates, methods, complete test data, and results; 21 CFR 211.84 requires sampling/testing of lots/components and allows some reliance on supplier reports of analysis only when supplier reliability is appropriately established, while retaining specific identity-testing requirements.

These regulations apply to drug-manufacturing contexts; MitoCore uses them here as strong quality-system examples, not as a universal legal template for every research COA. Strong traceability questions include whether the report lot number matches the product lot, whether the actual lot was tested or only a “representative sample,” whether the sample identifier is unique, whether test/report dates are plausible, and whether the report can be verified with the laboratory.

21 CFR 211.194 requires complete GMP laboratory records to include data such as graphs, charts, and spectra from laboratory instrumentation, appropriately identified to the lot/sample tested. Supporting chromatograms and spectra generally provide more transparency than a single typed result alone.

However, a chromatogram image by itself does not prove a report is authentic, a spectrum without sample traceability is limited, and raw data should not be interpreted by unqualified users as a replacement for validated analysis and review.

A few widely repeated claims about peptide purity, identity, and testing do not hold up against the guidance and literature they are often attributed to.